BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31479696)

  • 1. Ursodeoxycholic acid in pregnancy?
    de Vries E; Beuers U
    J Hepatol; 2019 Dec; 71(6):1237-1245. PubMed ID: 31479696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [-Therapy with ursodeoxycholic acid in primary biliary cirrhosis in pregnancy-].
    Rudi J; Schönig T; Stremmel W
    Z Gastroenterol; 1996 Mar; 34(3):188-91. PubMed ID: 8650973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
    Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
    J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
    Kotb MA
    Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
    Verma A; Jazrawi RP; Ahmed HA; Davis T; Bland JM; Benson M; Orchard RT; Theodossi A; Maxwell JD; Northfield TC
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1069-76. PubMed ID: 10524634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.
    Van Hoogstraten HJ; De Smet MB; Renooij W; Breed JG; Engels LG; Den Ouden-Muller JW; Rijk MC; Smit AM; Zwertbroek R; Hop WC; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Aliment Pharmacol Ther; 1998 Oct; 12(10):965-71. PubMed ID: 9798800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
    Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
    Levy C; Peter JA; Nelson DR; Keach J; Petz J; Cabrera R; Clark V; Firpi RJ; Morelli G; Soldevila-Pico C; Lindor K
    Aliment Pharmacol Ther; 2011 Jan; 33(2):235-42. PubMed ID: 21083674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    Corpechot C; Chazouillères O; Belnou P; Montano-Loza AJ; Mason A; Ebadi M; Eurich D; Chopra S; Jacob D; Schramm C; Sterneck M; Bruns T; Reuken P; Rauchfuss F; Roccarina D; Thorburn D; Gerussi A; Trivedi P; Hirschfield G; McDowell P; Nevens F; Boillot O; Bosch A; Giostra E; Conti F; Poupon R; Parés A; Reig A; Donato MF; Malinverno F; Floreani A; Russo FP; Cazzagon N; Verhelst X; Goet J; Harms M; van Buuren H; Hansen B; Carrat F; Dumortier J;
    J Hepatol; 2020 Sep; 73(3):559-565. PubMed ID: 32275981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two successive pregnancies after ursodeoxycholic acid therapy in a previously infertile woman with antimitochondrial antibody-negative primary biliary cirrhosis.
    Korkut E; Kisacik B; Akcan Y; Belenli O; Bicik Z; Yucel O
    Fertil Steril; 2005 Mar; 83(3):761-3. PubMed ID: 15749512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
    Khakoo NS; Sultan S; Reynolds JM; Levy C
    Dig Dis Sci; 2023 Apr; 68(4):1559-1573. PubMed ID: 36180756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.
    Chen J; Xue D; Gao F; Tao L; Li Y; Zhang Q; Wang R; Sun L; Yang X; Liu Y; Zhu B; Niu S; Wang X
    Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1352-1360. PubMed ID: 29889683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.
    Lindor KD; Dickson ER; Jorgensen RA; Anderson ML; Wiesner RH; Gores GJ; Lange SM; Rossi SS; Hofmann AF; Baldus WP
    Hepatology; 1995 Oct; 22(4 Pt 1):1158-62. PubMed ID: 7557866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incomplete response to ursodeoxycholic acid in primary biliary cholangitis: criteria, epidemiology, and possible mechanisms.
    Huang LX; Wang ZL; Jin R; Chen HS; Feng B
    Expert Rev Gastroenterol Hepatol; 2022; 16(11-12):1065-1078. PubMed ID: 36469627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis.
    Zhang H; Yang J; Zhu R; Zheng Y; Zhou Y; Dai W; Wang F; Chen K; Li J; Wang C; Li S; Liu T; Abudumijiti H; Zhou Z; Wang J; Lu W; Wang J; Xia Y; Zhou Y; Lu J; Guo C
    Drug Des Devel Ther; 2015; 9():567-74. PubMed ID: 25632224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
    Yuan Z; Jia G; Han Y
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
    Hosonuma K; Sato K; Yamazaki Y; Yanagisawa M; Hashizume H; Horiguchi N; Kakizaki S; Kusano M; Yamada M
    Am J Gastroenterol; 2015 Mar; 110(3):423-31. PubMed ID: 25732417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.